Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 14/20 | 0.45 |
| ▸ | ACACA | Q13085 | 7/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | SETD1B | Q9UPS6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12476320 | 0.86 | ACACB (0.56) | ACACBACACACYP2C9CYP2C19 | |
| SCHEMBL17050438 | 0.86 | ACACB (0.43) | ACACBACACACYP2C9CYP2C19PARP15 | |
| SCHEMBL17050442 | 0.84 | ACACB (0.43) | ACACBACACACYP2C9CYP2C19 | |
| SCHEMBL12476562 | 0.84 | ACACB (0.42) | ACACBCYP2C9CYP2C19ALDH1A1LMNA | |
| SCHEMBL17050444 | 0.83 | ACACB (0.44) | ACACBACACACYP2C9CYP2C19PARP15 | |
| SCHEMBL12476184 | 0.82 | ACACB (0.49) | ACACBACACACYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL12476606 | 0.81 | ACACB (0.42) | ACACBACACACYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL12476070 | 0.81 | ACACB (0.44) | ACACBACACAALDH1A1LMNAMAPT | |
| SCHEMBL12475958 | 0.81 | ACACB (0.38) | ACACBACACACYP2C9CYP2C19 | |
| SCHEMBL17050441 | 0.79 | ACACB (0.47) | ACACBACACACYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150246938-A1 | NOVEL OLEFIN DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2015-09-03 | — | — | US | disclosed |
| US-20150246938-A1 | NOVEL OLEFIN DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2015-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246938-A1 | NOVEL OLEFIN DERIVATIVE | ACSS2, ACACB, ACAT2 | ACACB 2/4885ACACA 10/4885CYP2C9 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.